WHO 2017 report had identified globally most important drug resistant pathogens, which urgently requires development of new antibiotics. The Antimicrobial Research Team of CSIR-IMTech has been working on these priority pathogens with unmet medical needs, namely,Mycobacterium tuberculosis(Mtb) and gram-negatives, for over a decade and has established novel screens, innovative models and robust platforms for understanding disease pathogenesis. CSIR-IMTECH is building a translational platform for infectious diseases drug discovery and development with specific focus on drug-resistant pathogens. Furthermore, CSIR-IMTECH has identified leads for further development as pre-clinical candidates. The objective of the project is to apply cutting-edge technologies to the discovery of high quality pre-clinical candidates in two verticals: (i) Tuberculosis and (ii) Gram-negatives. We intend to build a robust drug discovery portfolio and drive the early discovery projects into translational mode in collaboration with industry and clinical partners.